NextGen Biomed 2025
Summary:
As nearly all therapeutic antibodies move into the clinic with functional Fc domains, and over 45% of them Fc-engineered, developers can no longer afford to overlook the complexity and clinical impact of Fc-mediated effector functions.
This comprehensive workshop from NextGen Biomed 2025, led by Dr. Silvia Crescioli, Dr. Shashi Jatiani, and Dr. Ian Wilkinson (GammaProteins), walks through the nuanced interplay between Fab and Fc regions, the unpredictable consequences of Fc engineering, and why early, broad functional screening is critical for therapeutic success.
Highlights include:
- Why silencing Fc function isn’t always truly silent
- How tripartite Fc-FcR-antigen interactions can dramatically affect safety and efficacy
- Case studies revealing overlooked effector functions, like ADNP and ADEP, in anti-CD20 mAbs
- How SeromYx’s GCLP-certified platform enables antigen-specific Fc profiling at scale to support IND/BLA submissions
Authors:
Silvia Crescioli, PhD, Shashi Jatiani, PhD, Ian Wilkinson, PhD.
